toxicité (1) qualité de vie (1) industrie pharmaceutique (1) besoin (1) marketing (1) démocratie (1) décision (1) coût (1) cancer (1) survie (1) Diagnosis (1) Decision making (1) Context (1) Marketing (1) Treatment (1) Cancer (1) Methods (1) Transparency (1) Expertise (1) Views (1) Survival (1) Quality of life (1) Progress (1) Population (1) Patients (1) Oncologists (1) Months (1) Medical policy (1) Medical care (1) Marketing (1)